Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study investigates the clinical course of CDK4/6 inhibitor treated patients in the real-world setting among patients with breast cancer. CDK4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy, from patients with breast cancer that has spread to the other places in the body (metastatic) may help doctors learn more about cancer and the development of drug resistance in patients, and predict how well patients will respond to treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli pacjenci z rakiem piersi z przerzutami (ER+/HER2-) lub rakiem piersi we wczesnym stadium (HR+/HER2-) bez przerzutów do węzłów chłonnych, wysokiego ryzyka
- •Pacjenci leczeni lub leczeni wcześniej terapią opartą na ciklibie
- •Pacjenci mogą uczestniczyć zarówno w standardowym leczeniu, jak i w badaniach obserwacyjnych w szpitalach partnerskich
- •Pacjent musi rozumieć cel badania i podpisać świadomą zgodę zatwierdzoną przez komisję etyczną
✗ Disqualifies
- •Kobiety w ciąży lub karmiące piersią
- •Osoby niechętne lub niezdolne do przestrzegania wymogów badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 13, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Roswell Park Cancer Institute
Buffalo, United States
Trial contact
Agnieszka K. Witkiewicz
Agnieszka K. Witkiewicz
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.